MYOC

Across TCGA pan-cancer cohorts, MYOC mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MYOC data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MYOC mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MYOC expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where MYOC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.939	0.594	.005	63	view →
LUAD	OS	Median	II,III,IV	0.782	1.000	.004	22	view →
HNSC	OS	Median	All	0.956	1.000	.014	6	view →
PDAC	DFS	Median	All	0.543	0.828	.014	4	view →
LSCC	DFS	Quartile	II,III,IV	0.758	1.000	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MYOC–CCRCC (OS)

Open the CCRCC breakdown →